The treatment involves removing T cells from a patient’s blood, modifying them in a lab to fight cancer and then infusing them back into the patient. While J&J and Legend say they are doing everything they can to increase manufacturing, the process is basically bespoke, which means economies of scale don’t apply. Whether they will be able to quickly, and smoothly, increase capacity from about 1,000 shots annually to their stated goal of 10,000 shots by 2026 is the bigger question. Huang, the CEO, attributed the bump in sales to FDA approval to increase capacity at its New Jersey site. He added the companies are currently working on receiving a second FDA capacity approval this year, which would affect results in the first quarter of 2024.

Source: Wall Street Journal September 21, 2023 18:25 UTC